TITLE

Graves' disease treated with thyroid arterial embolization

AUTHOR(S)
Wei Zhao; Bu-Lang Gao; Min Tian; Gen-Fa Yi; Hui-Ying Yang; Li-Juan Shen3; Hong Li; Jin Shen
PUB. DATE
April 2009
SOURCE
Clinical & Investigative Medicine;Apr2009, Vol. 32 Issue 2, pE158
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: To study pathological changes in the thyroid gland of patients with Graves' disease (GD) treated with thyroid arterial embolization. Methods: Thirty-seven patients with GD were treated through transcatheter thyroid arterial embolization. Of these patients, twenty-two had biopsy of the thyroid gland at different time points before and after the embolization for the study of pathology. Serum thyroid hormones, TSH and TRAb were also studied at these time points. Thyroid size was evaluated in all patients using color Doppler ultrasound or CT scan. Results: Thyroid size decreased immediately or several days following embolization. Pathological study demonstrated mainly acute infarction and necrosis at 7 days post embolization. At 6 months, chronic inflammation and fibrous hyperplasia were the primary findings in the gland, and at 3 years following embolization, mesenchyma hyperplasia and follicle atrophy were primarily present in the embolized thyroid tissue. The thyroid hormones and TSH gradually resumed to normal range after embolization while TRAb decreased significantly. Conclusion: Thyroid arterial embolization can cause GD thyroid gland a series of pathological changes of acute ischemia and necrosis and later, chronic inflammation, fibroplasia and atrophy to decrease secretion of thyroid. The pathological changes within the thyroid gland after embolization form the basis of thyroid arterial embolization in treating GD hyperthyroidism.
ACCESSION #
37808706

 

Related Articles

  • Clinical Studies of Exposure to Perchlorate in the United States. Lewis E. Braverman // Thyroid;Sep2007, Vol. 17 Issue 9, p819 

    Perchlorate is a competitive inhibitor of the sodium/iodine symporter, decreasing the active transport of iodine into the thyroid. It was used as an antithyroid drug in the treatment of hyperthyroidism in the 1950s and 1960s but was discontinued because of the occasional occurrence of aplastic...

  • Síndrome Marine-Lenhart. Reporte de caso. Pinto, Miguel; Manrique, Helard // Revista Medica Herediana;jul-sep2011, Vol. 22 Issue 3, p143 

    A 34-year-old woman came to hospital with a recent history of asymptomatic diffuse thyroid enlargement and normal thyroid profile. Physical examination showed a palpable nodule in the left lobe. Ultrasound confirmed a solid nodule in the left lobe with increased Doppler color flow. The anti TPO...

  • Thyroid arterial embolization for the treatment of hyperthyroidism in a patient with thyrotoxic crisis. Wei Zhao; Bu-Lang Gao; Gen-Fa Yi; Hui-Ying Yang; Hong Li // Clinical & Investigative Medicine;Feb2009, Vol. 32 Issue 1, pE78 

    Purpose: We report a case of hyperthyroidism in a young woman caused by Graves' disease that was successfully treated with thyroid arterial embolization. Clinical details: A 35 year-old woman with a history of thyrotoxic crises was admitted after the last thyroid crisis. Thyroid arterial...

  • Oh, My! Has My Gay Gland Gone Awry? Schwartz, Katie // Echelon Magazine;Aug/Sep2010, p42 

    The article discusses the symptoms and resources of thyroid cancer and thyroid autoimmune diseases like Hashimoto's and Grave's diseases. The thyroid gland, located in the neck close to the throat and parathyroid, produces thyroid hormones that regulate metabolism. High thyroid hormone levels...

  • Enfermedad de Graves y cáncer de tiroides. Reporte de caso. Manrique-Hurtado, Helard; Pinto-Valdivia, Miguel; Acosta-Chacaltana, Max // Revista Medica Herediana;ene-mar2011, Vol. 22 Issue 1, p34 

    We report the case a 62-year-old woman with recent history of hyperthyroidism due to Graves' disease. Her medical history included treated rectal cancer. Physical exam showed a diffuse goiter with a nodule in the right thyroid lobe. Her thyroid profile was suppressed TSH and elevated thyroid...

  • Involvement of Inducible Costimulator Ligand (ICOSL) Expression in Thyroid Tissue in Hyperthyroidism of Graves' Disease Patients. Wang, Fengming; Yan, Tao; Chen, Lujun; Chen, Xuemin; Liu, Tong; Shen, Shuang; Li, Ting; Gao, Li; Wang, Ting; Sun, Jing; Liu, Cuiping; Wu, Haorong; Zhang, Xueguang; Chen, Lei // Journal of Clinical Immunology;Dec2012, Vol. 32 Issue 6, p1253 

    Background: The role of costimulatory molecules expressed on lymphocytes and thyrocytes in hyperthyroidism has attracted increasing attention and research has shown a close correlation between variant expression of these molecules on lymphocytes and thyrocytes and the development of GD....

  • Thyroid Hormones and Cytogenetic Outcomes in Backpack Sprayers Using Ethylenebis (dithiocarbamate) (EBDC) Fungicides in Mexico.  // Environmental Health Perspectives;Oct1997, Vol. 105 Issue 10, p1 

    Evaluates thyroid hormones and cytogenetic outcomes in backpack sprayers using ethylenebis fungicides in Mexico. Classification of ethylene thiourea (ETU) as carcinogen; Use of urinary ETU to compare exposure of cancer between the groups; Effects of ethylenebis on thyroid glands.

  • Intratracheal ectopic thyroid tissue: A case report and literature review. Byrd, Michael C.; Thompson, Lester D. R.; Wieneke, Jacqueline A. // ENT: Ear, Nose & Throat Journal;Jul2003, Vol. 82 Issue 7, p514 

    We discuss a case of intratracheal ectopic thyroid tissue (ETT) that was retrieved from the files of the Otorhinolaryngic-Head and Neck Pathology Registry at the Armed Forces Institute of Pathology. The patient was a 54-yearold man who had a history of papillary thyroid carcinoma, which had been...

  • Evaluation of mechanisms inducing thyroid toxicity and the ability of the enhanced OECD Test Guideline 407 to detect these changes. Cunha, G.; van Ravenzwaay, B. // Archives of Toxicology;Jul2005, Vol. 79 Issue 7, p390 

    The OECD has developed an “enhanced Test Guideline 407” (TG 407) protocol for detecting endocrine effects during the course of a 28-day testing scheme. This protocol has gone through a validation process with (anti)estrogenic and (anti)androgenic compounds and substances that affect...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics